UK pharma group posts ‘statistically significant’ trial results for treatment combined with Blenrep pulled in 2022 ...

(Alliance News) - GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory multiple myeloma, the third most common type of blood cancer.

Sun Pharmaceuticals Industries Ltd. also demonstrated strong performance at 13.1% ... Ltd. (8.6%), Alkem Laboratories Ltd. (7 ...

GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...

Approximately 44 million COPD cases were recorded in 2023 in the 7MM, expected to grow at a 1.4% CAGR through 2034. After ...

Saudi Arabia Pharmaceutical Drugs Market Projected To Witness Substantial Growth, 2024-2031: Pfizer Inc., Sanofi S. A. Saudi Arabia Pharmaceutical Drugs Market is estimated to be valued at US$ 12.60 ...

Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...

In a report released today, Peter Welford from Jefferies downgraded GlaxoSmithKline (GSK – Research Report) to a Hold, with a price ...

GSK celebrates 100 years in India with former MDs, highlighting resilience and reinvention in the pharmaceutical industry.

Concluded targeted enrollment of Phase 3 INDIGO trial evaluating obexelimab for the treatment of Immunoglobulin G4-Related ...

Andrew Witty became CEO of UnitedHealth Group in 2021, but this isn’t his first medical executive gig—he also served as CEO ...

A new generic version of varenicline – originally sold in the UK as Champix by Pfizer – has now been approved for use by the ...